<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00233415</url>
  </required_header>
  <id_info>
    <org_study_id>PANC0001</org_study_id>
    <secondary_id>PANC0001</secondary_id>
    <nct_id>NCT00233415</nct_id>
  </id_info>
  <brief_title>Cyberknife Radiosurgery for Locally Advanced Pancreatic Cancer</brief_title>
  <official_title>Phase II Study to Evaluate the Efficacy of Conventional Chemoradiotherapy Followed by Stereotactic Radiosurgery for Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      The purpose of the trial is to test the efficacy of combining conventional chemoradiotherapy&#xD;
      with radiosurgery for locally advanced pancreas cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the trial is to test the efficacy of treating locally advanced pancreatic&#xD;
      cancer with 5FU and concurrent conventional radiotherapy followed by precisely administered&#xD;
      single fraction of high-energy radiation using a radiosurgical technique.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Conventional Chemoradiotherapy Followed by Stereotactic Radiosurgery</measure>
  </primary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stereotactic Radiosurgery (Cyberknife)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:- Pancreatic tumors not to exceed 7.5 cm.&#xD;
&#xD;
          -  Histologically confirmed malignancies of the pancreas, (ampulla of Vater or&#xD;
             periampullary duodenum, tumors may be included when the head of pancreas is&#xD;
             secondarily involved and unresectable criteria are met).&#xD;
&#xD;
          -  Unresectable by CT criteria or unresectable at exploratory laparotomy or laparoscopy.&#xD;
             CT criteria for unresectability include encasement of the superior mesenteric vein&#xD;
             (SMV), portal vein (PV) or invasion of the celiac artery or superior mesenteric artery&#xD;
             (SMA).&#xD;
&#xD;
          -  Patients with metastatic disease may be treated if they are symptomatic from the&#xD;
             primary tumor.&#xD;
&#xD;
          -  Eastern Clinical Oncology Group performance status 0, 1 or 2. Exclusion&#xD;
             Criteria:Chemotherapy within 1 month of registration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Koong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>October 3, 2005</study_first_submitted>
  <study_first_submitted_qc>October 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2005</study_first_posted>
  <last_update_submitted>June 1, 2010</last_update_submitted>
  <last_update_submitted_qc>June 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Albert Koong</name_title>
    <organization>Stanford University School of Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

